bbo-8520
·Code: BBO-8520
bbo-8520: 1 clinical trial tracked.
bbo-8520 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about bbo-8520, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
Primary endpoint: Adverse Events
Interventionalopen350 targetStarted 2024-05Completion 2031-0938 sites · Australia, Canada, Denmark, Spain…TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)